Genocea Biosciences (NASDAQ: GNCA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
This is a breakdown of recent ratings and recommmendations for Genocea Biosciences and Inovio Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genocea Biosciences presently has a consensus price target of $21.75, suggesting a potential upside of 302.78%. Inovio Pharmaceuticals has a consensus price target of $20.90, suggesting a potential upside of 245.45%. Given Genocea Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Inovio Pharmaceuticals.
This table compares Genocea Biosciences and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
59.3% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 24.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 6.7% of Genocea Biosciences shares are owned by insiders. Comparatively, 10.6% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Genocea Biosciences and Inovio Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Genocea Biosciences||N/A||N/A||-$54.72 million||($2.03)||-2.66|
|Inovio Pharmaceuticals||$51.84 million||10.53||-$70.60 million||($1.08)||-5.60|
Genocea Biosciences has higher revenue, but lower earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Genocea Biosciences has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 2.75, indicating that its share price is 175% more volatile than the S&P 500.
Inovio Pharmaceuticals beats Genocea Biosciences on 7 of the 12 factors compared between the two stocks.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.